<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>101</order>
    <score>0.94002</score>
    <nct_id>NCT00245947</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00245947</url>
    <title>Study Evaluating ERB-041 in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: ERB-041</intervention_summary>
    <last_changed>September 9, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>102</order>
    <score>0.94</score>
    <nct_id>NCT02233062</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02233062</url>
    <title>Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Exclusive Enteral Nutrition Therapy</intervention_summary>
    <last_changed>September 5, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>103</order>
    <score>0.93921</score>
    <nct_id>NCT00162942</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00162942</url>
    <title>Study for the Treatment of Crohn's Disease With Adacolumn</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: Adacolumn; Device: Sham</intervention_summary>
    <last_changed>March 5, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>104</order>
    <score>0.93903</score>
    <nct_id>NCT02311660</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02311660</url>
    <title>Vagus Nerve Stimulation in Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: Vagus Nerve Stimulation Device</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>105</order>
    <score>0.93826</score>
    <nct_id>NCT02974322</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02974322</url>
    <title>A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: GED-0301; Drug: Placebo</intervention_summary>
    <last_changed>July 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>106</order>
    <score>0.93825</score>
    <nct_id>NCT03235180</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03235180</url>
    <title>Ultrasound Evaluation of Crohn's Disease</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Sulfur Hexafluoride; Device: Ultrasound Elastography; Device: Ultrasound Vascularity; Device: Magnetic Resonance Enterography (MRE)</intervention_summary>
    <last_changed>July 31, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>107</order>
    <score>0.9382</score>
    <nct_id>NCT01102855</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01102855</url>
    <title>Endomicroscopy and Crohn´s Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <last_changed>August 10, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>108</order>
    <score>0.93791</score>
    <nct_id>NCT00922415</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00922415</url>
    <title>Fecal Calprotectin as a Marker for Macroscopic Recurrence of Crohn's Disease After Intestinal Resection</title>
    <status open="N">Unknown status</status>
    <condition_summary>Complicated Crohn's Disease</condition_summary>
    <last_changed>December 15, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>109</order>
    <score>0.93754</score>
    <nct_id>NCT02199626</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02199626</url>
    <title>SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).</title>
    <status open="N">Completed</status>
    <condition_summary>Pediatric; Colon Capsule Endoscopy</condition_summary>
    <intervention_summary>Device: Second generation of colon capsule endoscopy (GIVEN IMAGING)</intervention_summary>
    <last_changed>July 23, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>110</order>
    <score>0.93749</score>
    <nct_id>NCT00740103</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00740103</url>
    <title>Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Semapimod</intervention_summary>
    <last_changed>August 22, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>111</order>
    <score>0.93745</score>
    <nct_id>NCT00613197</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00613197</url>
    <title>EPANOVA in Crohn's Disease, Study 1</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Epanova</intervention_summary>
    <last_changed>April 3, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>112</order>
    <score>0.9374</score>
    <nct_id>NCT00177866</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00177866</url>
    <title>Safety of Celecoxib in Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Celebrex; Drug: placebo</intervention_summary>
    <last_changed>July 28, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>113</order>
    <score>0.93698</score>
    <nct_id>NCT01738529</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01738529</url>
    <title>Characterization of Crohn's Disease at Confocal Laser Endomicroscopy (CLE) and Related to Disease Activity</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Device: CLE ileocolonoscopy</intervention_summary>
    <last_changed>February 17, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>114</order>
    <score>0.93648</score>
    <nct_id>NCT02445547</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02445547</url>
    <title>Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: UC-MSCs by peripheral intravenous infusion; Drug: received hormone maintenance therapy</intervention_summary>
    <last_changed>January 16, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>115</order>
    <score>0.93626</score>
    <nct_id>NCT03171246</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03171246</url>
    <title>CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Solid food-based intervention</intervention_summary>
    <last_changed>June 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>116</order>
    <score>0.9362</score>
    <nct_id>NCT00329550</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00329550</url>
    <title>Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab pegol (CZP); Biological: Certolizumab pegol (CZP); Biological: Certolizumab pegol (CZP)</intervention_summary>
    <last_changed>February 27, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>117</order>
    <score>0.9361</score>
    <nct_id>NCT00106314</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00106314</url>
    <title>An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Dehydroepiandrosterone [DHEA]</intervention_summary>
    <last_changed>October 17, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>118</order>
    <score>0.93589</score>
    <nct_id>NCT02225795</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02225795</url>
    <title>Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Hematopoietic stem cell transplantation</intervention_summary>
    <last_changed>March 28, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>119</order>
    <score>0.93574</score>
    <nct_id>NCT00304252</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00304252</url>
    <title>Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Interferon beta-1a</intervention_summary>
    <last_changed>August 4, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>120</order>
    <score>0.9355</score>
    <nct_id>NCT02213835</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02213835</url>
    <title>Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: Specific Carbohydrate diet (SCD)</intervention_summary>
    <last_changed>December 7, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>121</order>
    <score>0.93545</score>
    <nct_id>NCT01453946</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01453946</url>
    <title>Safety and Maintenance Study of Entocort for Children With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Entocort</intervention_summary>
    <last_changed>November 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>122</order>
    <score>0.93489</score>
    <nct_id>NCT02148185</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02148185</url>
    <title>Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: MT-1303</intervention_summary>
    <last_changed>September 10, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>123</order>
    <score>0.93488</score>
    <nct_id>NCT02272868</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02272868</url>
    <title>Fecal Microbial Transplant in Pediatric Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbial transplant; Drug: Normal Saline; Drug: rifaximin+omeprazole+miralax</intervention_summary>
    <last_changed>November 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>124</order>
    <score>0.93486</score>
    <nct_id>NCT02559037</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02559037</url>
    <title>Acupuncture and Moxibustion Treatment for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: Acupuncture-moxibustion; Device: Placebo acupuncture-moxibustion</intervention_summary>
    <last_changed>July 27, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>125</order>
    <score>0.93483</score>
    <nct_id>NCT00496548</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00496548</url>
    <title>Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Fecal calprotectin; Procedure: Urinary PGE-M Level</intervention_summary>
    <last_changed>April 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>126</order>
    <score>0.93472</score>
    <nct_id>NCT01986127</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01986127</url>
    <title>Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab; Drug: placebo</intervention_summary>
    <last_changed>March 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>127</order>
    <score>0.93466</score>
    <nct_id>NCT02891226</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02891226</url>
    <title>A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Mirikizumab; Drug: Placebo</intervention_summary>
    <last_changed>July 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>128</order>
    <score>0.93461</score>
    <nct_id>NCT02951650</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02951650</url>
    <title>Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Device: Cyberonics VNS</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>129</order>
    <score>0.93456</score>
    <nct_id>NCT01765998</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01765998</url>
    <title>The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Probiotic; Drug: Placebo</intervention_summary>
    <last_changed>January 10, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>130</order>
    <score>0.93451</score>
    <nct_id>NCT02193750</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02193750</url>
    <title>Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Placebo; Dietary Supplement: Moderate Oligosaccharide Group; Dietary Supplement: High Oligosaccharide Group</intervention_summary>
    <last_changed>October 31, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>131</order>
    <score>0.93443</score>
    <nct_id>NCT00755937</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00755937</url>
    <title>Remicade® Crohn's Disease Registry Across Canada (Study P02793)</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Data collection post infusion</intervention_summary>
    <last_changed>May 26, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>132</order>
    <score>0.93437</score>
    <nct_id>NCT00114465</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00114465</url>
    <title>VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: VSL#3; Other: Placebo</intervention_summary>
    <last_changed>September 17, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>133</order>
    <score>0.93414</score>
    <nct_id>NCT01233310</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01233310</url>
    <title>Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <last_changed>August 22, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>134</order>
    <score>0.93411</score>
    <nct_id>NCT00663117</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00663117</url>
    <title>The Effects of Naltrexone on Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammation; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Naltrexone-HCl; Drug: Placebo</intervention_summary>
    <last_changed>May 16, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>135</order>
    <score>0.9341</score>
    <nct_id>NCT00780949</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00780949</url>
    <title>Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: intestinal biopsies</intervention_summary>
    <last_changed>August 2, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>136</order>
    <score>0.93381</score>
    <nct_id>NCT00434551</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00434551</url>
    <title>MACCS: Multicenter Australian CE in Patients With Suspected Crohn's Disease Study</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Diseases</condition_summary>
    <last_changed>March 25, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>137</order>
    <score>0.93362</score>
    <nct_id>NCT02389790</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02389790</url>
    <title>Extension Study of MT-1303 in Subjects With Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: MT-1303</intervention_summary>
    <last_changed>October 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>138</order>
    <score>0.9336</score>
    <nct_id>NCT00308438</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00308438</url>
    <title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Teduglutide (ALX-0600)</intervention_summary>
    <last_changed>November 10, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>139</order>
    <score>0.9335</score>
    <nct_id>NCT00206713</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00206713</url>
    <title>Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Sargramostim (Leukine); Drug: Placebo</intervention_summary>
    <last_changed>December 2, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>140</order>
    <score>0.93346</score>
    <nct_id>NCT02610101</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02610101</url>
    <title>Nutritional Therapy Study in Pediatric Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Traditional SCD Diet; Other: Modified SCD Diet; Other: Whole foods diet</intervention_summary>
    <last_changed>April 18, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>141</order>
    <score>0.93337</score>
    <nct_id>NCT02185014</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02185014</url>
    <title>Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>August 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>142</order>
    <score>0.93328</score>
    <nct_id>NCT02065570</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02065570</url>
    <title>Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>July 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>143</order>
    <score>0.93307</score>
    <nct_id>NCT00417391</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00417391</url>
    <title>Phase II Study of RR110 in Patients With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: RR110 (Tamibarotene); Drug: RR110 (Tamibarotene)</intervention_summary>
    <last_changed>May 25, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>144</order>
    <score>0.93281</score>
    <nct_id>NCT00207675</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00207675</url>
    <title>A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: infliximab</intervention_summary>
    <last_changed>May 16, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>145</order>
    <score>0.93276</score>
    <nct_id>NCT01523106</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01523106</url>
    <title>L-carnitine to Treat Fatigue Associated With Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease; Fatigue</condition_summary>
    <intervention_summary>Drug: L-carnitine; Other: Placebo</intervention_summary>
    <last_changed>January 16, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>146</order>
    <score>0.93274</score>
    <nct_id>NCT00731172</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00731172</url>
    <title>A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Drug: glatiramer acetate; Drug: placebo</intervention_summary>
    <last_changed>March 1, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>147</order>
    <score>0.93269</score>
    <nct_id>NCT00562887</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00562887</url>
    <title>Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Placebo; Biological: ABT-874; Biological: ABT-874</intervention_summary>
    <last_changed>August 18, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>148</order>
    <score>0.93267</score>
    <nct_id>NCT01218360</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01218360</url>
    <title>Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Physician standard-of-care</intervention_summary>
    <last_changed>March 18, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>149</order>
    <score>0.93249</score>
    <nct_id>NCT00509639</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00509639</url>
    <title>Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: 10% Metronidazole Ointment</intervention_summary>
    <last_changed>December 12, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>150</order>
    <score>0.9322</score>
    <nct_id>NCT02877134</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02877134</url>
    <title>Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: JNJ-64304500; Drug: Placebo; Drug: Ustekinumab</intervention_summary>
    <last_changed>July 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>151</order>
    <score>0.93173</score>
    <nct_id>NCT00488085</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00488085</url>
    <title>Crohn’s Disease, Obesity and Disease Severity</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn’s Disease, Obesity</condition_summary>
    <last_changed>June 18, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>152</order>
    <score>0.93161</score>
    <nct_id>NCT00042055</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00042055</url>
    <title>CP-461 for the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CP-461</intervention_summary>
    <last_changed>October 14, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>153</order>
    <score>0.93108</score>
    <nct_id>NCT01428115</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01428115</url>
    <title>Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab</title>
    <status open="N">Completed</status>
    <condition_summary>Severe Crohn's Disease; Anxiety</condition_summary>
    <last_changed>October 31, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>154</order>
    <score>0.93108</score>
    <nct_id>NCT00113503</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00113503</url>
    <title>Imuran Dosing in Crohn's Disease Study</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: IMURAN (azathioprine)</intervention_summary>
    <last_changed>January 12, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>155</order>
    <score>0.93104</score>
    <nct_id>NCT00715117</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00715117</url>
    <title>The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Naltrexone; Other: Placebo, sugar pill</intervention_summary>
    <last_changed>May 29, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>156</order>
    <score>0.93069</score>
    <nct_id>NCT03172143</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03172143</url>
    <title>Mesenteric Sparing for the Prevention of Recurrent Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Mesenteric Sparing Ileocolic Resection; Procedure: High Ligation Ileocolic Resection</intervention_summary>
    <last_changed>July 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>157</order>
    <score>0.93068</score>
    <nct_id>NCT01932658</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01932658</url>
    <title>Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Hematopoietic stem cell transplantation</intervention_summary>
    <last_changed>April 13, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>158</order>
    <score>0.93067</score>
    <nct_id>NCT00132184</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00132184</url>
    <title>Vitamin D Treatment for Crohn´s Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Drug: Vitamin D</intervention_summary>
    <last_changed>April 12, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>159</order>
    <score>0.93062</score>
    <nct_id>NCT02676622</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02676622</url>
    <title>Autologous Stem Cell Transplant for Refractory Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: mobilization of stem cells to prepare for Leukapheresis; Other: Leukapheresis- Collection of stem cells; Drug: Preparative regimen 4-6 weeks after Leukapheresis; Other: Stem Cell Transplant; Drug: Low-dose IL-2 administration</intervention_summary>
    <last_changed>February 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>160</order>
    <score>0.93046</score>
    <nct_id>NCT01316939</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01316939</url>
    <title>GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A</intervention_summary>
    <last_changed>March 13, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>161</order>
    <score>0.9301</score>
    <nct_id>NCT00221026</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00221026</url>
    <title>Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Methoxsalen +ECP; Procedure: Extracorporeal Photopheresis</intervention_summary>
    <last_changed>October 18, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>162</order>
    <score>0.93004</score>
    <nct_id>NCT02531113</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02531113</url>
    <title>Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: RPC1063</intervention_summary>
    <last_changed>May 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>163</order>
    <score>0.92988</score>
    <nct_id>NCT00445939</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00445939</url>
    <title>A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: adalimumab; Biological: adalimumab; Biological: placebo</intervention_summary>
    <last_changed>June 20, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>164</order>
    <score>0.92975</score>
    <nct_id>NCT02539849</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02539849</url>
    <title>Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: FOS; Drug: Adalimumab</intervention_summary>
    <last_changed>June 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>165</order>
    <score>0.92926</score>
    <nct_id>NCT01245088</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01245088</url>
    <title>Chondroitin Sulfate for Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: chondroitin sulfate</intervention_summary>
    <last_changed>August 29, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>166</order>
    <score>0.92905</score>
    <nct_id>NCT02015793</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02015793</url>
    <title>Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab; Biological: Placebo for adalimumab</intervention_summary>
    <last_changed>April 8, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>167</order>
    <score>0.92902</score>
    <nct_id>NCT01070303</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01070303</url>
    <title>Remission in Subjects With Crohn's Disease, Open Label Extension</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab 40 mg eow or ew</intervention_summary>
    <last_changed>April 7, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>168</order>
    <score>0.92896</score>
    <nct_id>NCT01199302</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01199302</url>
    <title>Safety Study in Subjects With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: AMG 827</intervention_summary>
    <last_changed>December 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>169</order>
    <score>0.92884</score>
    <nct_id>NCT02874495</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02874495</url>
    <title>Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Behavioral: Psychological tests; Device: Magnetic Resonance Imaging; Behavioral: Heart Rate Variability</intervention_summary>
    <last_changed>August 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>170</order>
    <score>0.92871</score>
    <nct_id>NCT03167437</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03167437</url>
    <title>Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vorinostat</intervention_summary>
    <last_changed>August 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>171</order>
    <score>0.92865</score>
    <nct_id>NCT02096861</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02096861</url>
    <title>Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: CT-P13; Biological: Remicade</intervention_summary>
    <last_changed>March 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>172</order>
    <score>0.92861</score>
    <nct_id>NCT02871635</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02871635</url>
    <title>BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: BI 695501; Drug: HUMIRA</intervention_summary>
    <last_changed>July 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>173</order>
    <score>0.92858</score>
    <nct_id>NCT01631435</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01631435</url>
    <title>PillCam® Platform With the PillCam Crohn's Disease Capsule</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Pillcam colon capsule and PillCam™ Prep Procedure; Device: Ileocolonoscopy</intervention_summary>
    <last_changed>March 11, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>174</order>
    <score>0.92854</score>
    <nct_id>NCT02249078</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02249078</url>
    <title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: E6011; Drug: Placebo</intervention_summary>
    <last_changed>November 4, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>175</order>
    <score>0.9284</score>
    <nct_id>NCT01541579</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01541579</url>
    <title>Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Cx601; Other: Saline solution</intervention_summary>
    <last_changed>November 30, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>176</order>
    <score>0.92833</score>
    <nct_id>NCT01510431</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01510431</url>
    <title>Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: PROCHYMAL (remestemcel-L)</intervention_summary>
    <last_changed>October 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>177</order>
    <score>0.9283</score>
    <nct_id>NCT02622763</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02622763</url>
    <title>Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Tolerogenic Dendritic Cells</intervention_summary>
    <last_changed>June 21, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>178</order>
    <score>0.92823</score>
    <nct_id>NCT00317369</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00317369</url>
    <title>A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: OPC-6535(Tetomilast)</intervention_summary>
    <last_changed>April 28, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>179</order>
    <score>0.92787</score>
    <nct_id>NCT00152425</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00152425</url>
    <title>Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab Pegol (CDP870)</intervention_summary>
    <last_changed>September 6, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>180</order>
    <score>0.92787</score>
    <nct_id>NCT01090817</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01090817</url>
    <title>An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Mesenchymal stromal cells (MSC) for infusion</intervention_summary>
    <last_changed>June 7, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>181</order>
    <score>0.92786</score>
    <nct_id>NCT01545050</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01545050</url>
    <title>Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429</intervention_summary>
    <last_changed>July 24, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>182</order>
    <score>0.92758</score>
    <nct_id>NCT00207766</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00207766</url>
    <title>A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: infliximab or placebo</intervention_summary>
    <last_changed>April 26, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>183</order>
    <score>0.92736</score>
    <nct_id>NCT02324699</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02324699</url>
    <title>Corticosteroids With Vedolizumab in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Prednisone; Drug: Placebo; Drug: Vedolizumab</intervention_summary>
    <last_changed>June 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>184</order>
    <score>0.92728</score>
    <nct_id>NCT00796250</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00796250</url>
    <title>Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Infliximab; Drug: AZA; Drug: Placebo Prednisolone; Drug: Prednisolone; Drug: AZA; Biological: Placebo Infliximab</intervention_summary>
    <last_changed>March 21, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>185</order>
    <score>0.92728</score>
    <nct_id>NCT00138840</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00138840</url>
    <title>Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: STA-5326 mesylate</intervention_summary>
    <last_changed>December 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>186</order>
    <score>0.9269</score>
    <nct_id>NCT02760836</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02760836</url>
    <title>Predictive Model of Clinical Outcomes Using Web-based Self-reporting Symptom Diary for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>December 26, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>187</order>
    <score>0.92688</score>
    <nct_id>NCT01659762</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01659762</url>
    <title>A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: autologous mesenchymal stromal cell</intervention_summary>
    <last_changed>October 13, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>188</order>
    <score>0.92685</score>
    <nct_id>NCT02209792</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02209792</url>
    <title>Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: BIBR 796 BS, 5 mg; Drug: BIBR 796 BS, 20 mg</intervention_summary>
    <last_changed>August 5, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>189</order>
    <score>0.92657</score>
    <nct_id>NCT02048618</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02048618</url>
    <title>Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GLPG0634; Drug: Placebo</intervention_summary>
    <last_changed>February 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>190</order>
    <score>0.92652</score>
    <nct_id>NCT01393626</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01393626</url>
    <title>A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550</intervention_summary>
    <last_changed>March 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>191</order>
    <score>0.92617</score>
    <nct_id>NCT00358683</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00358683</url>
    <title>A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab pegol</intervention_summary>
    <last_changed>May 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>192</order>
    <score>0.92601</score>
    <nct_id>NCT00269841</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00269841</url>
    <title>An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab 10 mg/kg; Drug: Infliximab 5 mg/kg; Drug: Placebo</intervention_summary>
    <last_changed>November 3, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>193</order>
    <score>0.92597</score>
    <nct_id>NCT02148718</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02148718</url>
    <title>Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Crohn's Disease</condition_summary>
    <intervention_summary>Biological: ADALIMUMAB</intervention_summary>
    <last_changed>February 15, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>194</order>
    <score>0.92596</score>
    <nct_id>NCT02084290</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02084290</url>
    <title>Evaluating a Shared Decision Making Program for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Behavioral: Shared Decision Making Program</intervention_summary>
    <last_changed>October 27, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>195</order>
    <score>0.92577</score>
    <nct_id>NCT00101946</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00101946</url>
    <title>Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: 683699</intervention_summary>
    <last_changed>April 10, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>196</order>
    <score>0.92569</score>
    <nct_id>NCT01714726</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01714726</url>
    <title>Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: MEDI2070; Drug: placebo; Drug: MEDI2070</intervention_summary>
    <last_changed>May 9, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>197</order>
    <score>0.92499</score>
    <nct_id>NCT02763293</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02763293</url>
    <title>Osteopathy Non-manipulative in Patients With Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <intervention_summary>Other: Manual Therapy</intervention_summary>
    <last_changed>July 22, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>198</order>
    <score>0.92477</score>
    <nct_id>NCT02097797</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02097797</url>
    <title>Impact of the Fecal Flora Transplantation on Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Fecal Transplantation; Other: Sham Transplantation</intervention_summary>
    <last_changed>August 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>199</order>
    <score>0.92449</score>
    <nct_id>NCT01434693</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01434693</url>
    <title>Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Trichuris suis ova; Other: Placebo</intervention_summary>
    <last_changed>May 17, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>200</order>
    <score>0.92437</score>
    <nct_id>NCT02899013</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02899013</url>
    <title>Description of Perianal Lesions in a Cohort of Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: No intervention</intervention_summary>
    <last_changed>September 12, 2016</last_changed>
  </clinical_study>
</search_results>
